Because of the large amount of prostate cancer screening there has been a major shift in initial staging in prostate cancer in western countries, with the incidence of metastases at diagnosis decreasing from over 50% in the 1970s to currently less than 10%. Despite this very significant drop in late stage diagnoses prostate cancer is [...]
Xgeva, also known as denosumab, is an injectable medication (injected once a month subcutaneously under the skin in the doctor’s office) that is used to prevent bone fractures and spinal cord compression caused by bone metastases in breast and prostate cancer survivors. Solid tumors in the bone, which is a common site for individuals with [...]
The development of bone metastases is often been viewed as having significant negative implications for long term survival in men with metastatic castrate resistant prostate cancer (mCRPC). It is generally believed that bone metastases prognosticates a negative impact on both their quality of life and on survival. Contradicting this commonly held belief has been some [...]
Many of our doctors are constantly vigilant about our developing skeletal related issues. Having advanced prostate cancer and receiving treatment for this disease increases our odds of developing skeletal issues which affect both our quality of life and our mortality. Drugs like denosumab (Xgeva) and zoledronic acid (Zometa) are important in delaying the onset of [...]
Men who develop bone metastases have often been viewed as having developed a significant negative change that prognosticates a negative impact on both their quality of life and on their survival. Contradicting this commonly held belief has been some research which has identified a subgroup of men with advanced prostate cancer with bone metastases who [...]